Aurinia Pharmaceuticals (AUPH): Notes From KOL Breakfast

October 12, 2016 10:14 AM EDT
Get Alerts AUPH Hot Sheet
Price: $2.38 +0.85%

Rating Summary:
    2 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 13 | Down: 22 | New: 54
Trade AUPH Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

FBR Capital analyst, Vernon Bernadino, reiterated his Outperform rating on shares of Aurinia Pharmaceuticals (NASDAQ: AUPH) after attending a key opinion leader breakfast event hosted on September 30 by Aurinia Pharmaceuticals.

AUPH announced detailed analyses updating the August results from the AURA-LV (AURA) Phase IIb clinical trial with voclosporin (VS) in patients with active lupus nephritis (LN). The results were impressive as AURA became the first study in LN to meet its primary and secondary outcome measures (1OM and 2OM, respectively). The analyst believes this alone differentiates VS from other lupus therapies.

He went farther saying "We think there is potential for gaining VS accelerated approval. However, our position remains full approval will require conducting a Phase III trial with a design similar to AURA but larger to confirm the safety and outcomes observed in AURA".

No change to the price target of $9.

For an analyst ratings summary and ratings history on Aurinia Pharmaceuticals click here. For more ratings news on Aurinia Pharmaceuticals click here.

Shares of Aurinia Pharmaceuticals closed at $4.47 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Add Your Comment